SBLENDORIO GLENN 4
4 · 4D Molecular Therapeutics, Inc. · Filed Jun 18, 2026
Research Summary
AI-generated summary of this filing
4D Molecular Therapeutics (FDMT) Director Glenn Sblendorio Receives Award
What Happened Glenn Sblendorio, a director of 4D Molecular Therapeutics (FDMT), received a 50,000-share derivative award on June 17, 2026. The award is reported at an acquisition price of $0.00 (i.e., a compensatory stock-option type grant) and no cash was exchanged. This is an award/compensation grant rather than a market purchase or sale.
Key Details
- Transaction date: June 17, 2026; Form 4 filed June 18, 2026 (timely filing).
- Instrument: Derivative award (stock option grant) for 50,000 shares; acquisition price reported as $0.00; total reported cash value $0.
- Vesting (per filing footnotes): 1/3 vests on June 17, 2027, then in equal monthly installments thereafter until fully vested on June 17, 2029. The options also vest in full upon a Change in Control.
- Grant mechanics: Automatically granted under the company’s non-employee director compensation program.
- Shares owned after transaction: Not specified in the provided excerpt.
Context This was a routine director compensation grant (derivative/option award), not an exercise or sale. The award does not represent immediate sale proceeds or a cash purchase; vesting schedule determines when the director can exercise the options. Such grants are common for non-employee directors and primarily reflect compensation policy rather than an immediate insider market signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-06-17+50,000→ 50,000 totalExercise: $9.42Exp: 2036-06-16→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
- [F2]The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).